Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects

NCT02223832 | Completed Phase 1

• 1 other identifier: AC-058-107
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This is a study to evaluate the relative pharmacokinetic properties and the tolerability and safety of ACT-128800 in Japanese and Caucasian healthy male and female subjects after single-dose administration.

Conditions

Healthy

Keywords

ACT-128800; Safety; Tolerability; Pharmacokinetics

Outcome Measures

Primary Outcomes (11)

• Change in systolic blood pressure from baseline up to end of study

  Blood pressure shall be measured using an automatic oscillometric device, always on the leading (writing) arm. Measurements shall be taken in the supine position after having rested for at least a 5 min period.

  Up to 10 days

• Change in diastolic blood pressure from baseline up to end of study

  Blood pressure shall be measured using an automatic oscillometric device, always on the leading (writing) arm. Measurements shall be taken in the supine position after having rested for at least a 5 min period.

  Up to 10 days

• Change in pulse rate from baseline up to end of study

  Pulse rate shall be measured using an automatic oscillometric device, always on the leading (writing) arm. Measurements shall be taken in the supine position after having rested for at least a 5 min period.

  Up to 10 days

• Change in body temperature from baseline up to end of study

  Body temperature shall be measured in a supine position using the same thermometer throughout the study.

  Up to 10 days

• Change in forced expiratory volume in 1 second (FEV1) from baseline up to end of study

  FEV1 assessments shall be performed in a standardized manner as per the American Thoracic Society standards. Three good test breaths will be measured; the highest FEV1 value from these three breath tests will be recorded.

  Up to 10 days

• Change in forced vital capacity (FVC) from baseline up to end of study

  FVC assessments shall be performed in a standardized manner as per the American Thoracic Society standards. Three good test breaths will be measured; the highest FVC value from these three breath tests will be recorded.

  Up to 10 days

• Number of treatment-emergent abnormalities on physical examination up to end of study

  Physical examination (i.e., inspection, percussion, palpation, and auscultation) shall be performed during the course of the study.

  Up to 10 days

• Change in heart rate from baseline up to end of study

  Heart rate shall be measured using standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period.

  Up to 10 days

• Change in QT interval (time interval from beginning of the Q wave until end of the T wave) calculated according to Bazett's correction (QTcB) from baseline up to end of study

  QTcB shall be determined using standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. The QTcB interval is the QT interval corrected for heart rate with Bazett's formula (QTcB = QT/RR\^0.5 where RR is 60/heart rate).

  Up to 10 days

• Change in QT interval (time interval from beginning of the Q wave until end of the T wave) calculated according to Fridericia's correction (QTcF) from baseline up to end of study

  QTcF shall be determined using standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period. The QTcF interval is the QT interval corrected for heart rate with Fridericia's formula (QTcF = QT/RR\^0.33 where RR is 60/heart rate).

  Up to 10 days

• Number of treatment-emergent electrocardiogram abnormalities up to end of study

  Electrocardiogram abnormalities shall be determined using standard 12-lead electrocardiogram recorded at rest with the subject in the supine position for a 5-minute period.

  Up to 10 days

Secondary Outcomes (6)

• Maximum plasma concentration (Cmax) of ACT-128800

  144 hours

• Time to maximum plasma concentration (tmax) of ACT-128800

  144 hours

• Area under the plasma concentration-time curve (AUC(0-t)) of ACT-128800

  144 hours

• Area under the plasma concentration-time curve (AUC(0-infinity)) of ACT-128800

  144 hours

• Plasma half life (t1/2) of ACT-128800

  144 hours

Study Arms (1)

ACT-128800

EXPERIMENTAL

A single oral dose of 40 mg ACT-128800 will be administered as 1 capsule given in the fasted state in the morning

Drug: ACT-128800

Interventions

ACT-128800 DRUG

ACT-128800

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Signed informed consent prior to any study-mandated procedure.
• Japanese or Caucasian. (Japanese subjects: both parents of the subject are Japanese \[born in Japan\]. Caucasian subjects: both parents of the subject are Caucasian).
• Body mass index between 18 and 28 kg/m\^2, inclusive.
• Women not of childbearing potential:
• Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to drug intake on Day 1; use a reliable method of contraception and continue this contraception for the duration of the study and for at least 2 months after study drug intake. In addition, her partner must use a condom.
• Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and heart rate (HR) 50-95 beats per minute (inclusive).
• lead electrocardiogram without clinically relevant abnormalities at screening.
• Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent at screening.
• Negative results from urine drug screen at screening.
• Ability to communicate well with the Investigator (if necessary with the help of an interpreter) and to understand and comply with the requirements of the study.

You may not qualify if:

• Electrocardiograph PQ/PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) \> 200 milliseconds at screening.
• Nursing woman.
• History of asthma or chronic obstructive pulmonary disease.
• Known hypersensitivity to any excipients of the drug formulation.
• Treatment with another investigational drug within 3 months prior to screening.
• Excessive caffeine consumption, defined as \> 800 mg per day at screening.
• History or clinical evidence of any disease and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of the study drug.
• Any cardiac condition or illness, including ECG abnormalities, with a potential to increase the cardiac risk of the subject.
• Smoking within the last month prior to screening.
• Any immunosuppressive treatment within 6 weeks before study drug administration.
• Previous treatment with any prescribed or over-the-counter medications within 2 weeks prior to screening.
• Loss of 250 mL or more of blood within 3 months prior to screening.
• Lymphopenia (\< 1,000 lymphocytes/μL).
• Viral, fungal, bacterial or protozoal infection within 4 weeks before study drug administration.
• Positive results from the hepatitis serology, except for vaccinated subjects, at screening.

Sponsors & Collaborators

• Actelion: lead

Study Sites (1)

Hawaii Clinical Research Center

Honolulu, Hawaii, 96813, United States

Location

MeSH Terms

Interventions

ponesimod

Study Officials

• Patrick Brossard, PhD

  Actelion Pharmaceuticals Limited

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 21, 2014
• First Posted: August 22, 2014
• Study Start: February 1, 2009
• Primary Completion: April 1, 2009
• Study Completion: April 1, 2009
• Last Updated: August 22, 2014

Record last verified: 2014-08

Locations

US (1)